Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 6Unknown 2Not yet recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Lymphoma, Mantle-Cell 2Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma 1

Interventions

obinutuzumab 3fludarabine 3Rituximab 3Cyclophosphamide 3zanubrutinib 2orelabrutinib 2glofitamab 2Bendamustine Hydrochloride 2venetoclax 1tafasitamab 1resiniferatoxin 1polatuzumab vedotin 1pirtobrutinib 1Specimen Handling 1Magnetic Resonance Spectroscopy 1Interleukin-2 1CT-P10 1Bortezomib 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Not yet recruiting × Lymphoma, Mantle-Cell × orelabrutinib × Clear all
NCT07206264 2025-10-03

ADAPT-MCL

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Not yet recruiting
45 enrolled
Lymphoid

Lymphoma, Lymphoma, Mantle-Cell

NCT06656221 2024-11-19

A Prospective, Single-Center Study Evaluating the Efficacy and Safety of Glofitamab Combined With Orelabrutinib and Bortezomib in Patients With High-Risk Mantle Cell Lymphoma

Ruijin Hospital

Phase 2 Not yet recruiting
29 enrolled
Lymphoid

Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡